Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera (NASDAQ: NTRA) launched EDEN, a large U.S. prospective study to evaluate a non-invasive prenatal screening test for early risk assessment of preeclampsia and other adverse pregnancy outcomes. The study plans to enroll up to 7,500 participants at 9–15 weeks' gestation and combines cfDNA, additional analytes, and clinical data.
EDEN builds on prior research linking cfDNA markers to pregnancy complications and aims to detect earlier-onset and more severe preeclampsia with routine prenatal data.
Natera (NASDAQ: NTRA) submitted a premarket approval (PMA) to the U.S. FDA for Signatera CDx to detect molecular residual disease (MRD) in muscle-invasive bladder cancer (MIBC) patients who may benefit from atezolizumab.
The PMA is supported by randomized, double-blind phase 3 IMvigor011 data showing Signatera-guided therapy improved disease-free and overall survival for Signatera-positive patients, while Signatera-negative patients had low recurrence risk without adjuvant immunotherapy. Results were presented at ESMO and published in The New England Journal of Medicine.
Natera (NASDAQ: NTRA) completed enrollment in ACES-EMB, the first randomized-controlled trial comparing donor-derived cell-free DNA (dd-cfDNA) surveillance with routine endomyocardial biopsy (EMB) for heart transplant rejection monitoring.
The trial enrolled >300 patients across 17 U.S. transplant centers; participants randomized at one month post-transplant will be followed for 12 months.
Natera (NASDAQ: NTRA) announced a prospective clinical trial of the Prospera dd-cfDNA test in 78 lung-transplant recipients that evaluated whether monitoring could allow omission of the routine 9-month transbronchial biopsy. Prospera testing at ~8 months classified patients as low risk (<1.0% dd-cfDNA) or high risk (≥1.0%). Physicians omitted the 9-month biopsy in ~75% of low-risk patients. Over the next 3 months and at 12 months, patients who omitted the biopsy showed similar acute rejection rates, spirometry, and donor-specific antibody outcomes, and ~95% had no treated acute rejection at one year.
Natera (NASDAQ: NTRA) published a peer-reviewed validation of its Latitude tissue-free MRD (tfMRD) assay in colorectal cancer in npj Precision Oncology, analyzing 1,230 timepoints from 195 patients in the GALAXY trial.
Key results: longitudinal sensitivity 84.4% with a median lead time of 4.6 months before radiographic recurrence; sample-level specificity 97.2% and patient-level specificity 92.1%; MRD-positivity strongly prognostic (HR 10 in MRD setting; HR 31.9 in surveillance; p<0.001). In high-risk stage II/III patients, MRD-positive status predicted substantial adjuvant chemotherapy benefit (adj.HR=0.014, P<0.0001). The study supports a MolDX submission to CMS and notes Latitude complements tumor-informed Signatera when tissue is unavailable.
Natera (NASDAQ: NTRA) announced that the EXPAND clinical trial of its Fetal Focus™ single gene NIPT (sgNIPT) will be presented as an oral plenary at the Society for Maternal Fetal Medicine (SMFM) meeting, February 8-13, 2026.
EXPAND is a prospective, blinded trial validating Fetal Focus, which uses Natera’s LinkedSNP™ technology to assess inheritance of disease-causing variants across 21 genes for serious, early-onset conditions. The oral plenary will present key results, study design, and confirmation of outcomes against genetic truth. Natera will also present VANISH data validating Panorama™ NIPT interpretation in vanishing twin pregnancies and other related posters and oral presentations on February 11–12, 2026.
Natera (NASDAQ: NTRA)300,000 patients tested with Signatera and reportedly produces statistically and clinically significant enhancements in recurrence risk assessment and outcomes prediction. Data are expected to be presented at an upcoming conference ahead of research and clinical launches. The program builds on prior AI efforts and ongoing collaborations, including initiatives with NVIDIA, to scale high-performance biological modeling.
Natera (NASDAQ:NTRA)NVIDIA to scale multimodal AI foundation models for precision medicine by integrating Natera’s longitudinal in vivo datasets and ML models with NVIDIA’s compute, libraries, and AI frameworks.
Key elements: use of Parabricks, BioNeMo, and NeMo Agent Toolkit; NeoSelect and NeoPredict algorithms with claimed outperformance versus peers (neoantigen ranking and >2x improvement in immunotherapy response hazard ratios); early engineering gains of -75.7% run time, -59.2% cost, and +45.5% training speed.
Natera (NASDAQ: NTRA) reported preliminary unaudited results for Q4 and full-year 2025 showing strong growth: Q4 revenue ≈ $660 million (+39% vs Q4 2024) and FY 2025 revenue ≈ $2.3 billion (+35% vs FY 2024). Q4 tests processed were ≈ 923,600 (+17% YoY) and FY tests ≈ 3,525,500 (+15% YoY). Oncology volume rose sharply: Q4 oncology tests ≈ 233,300 (+55% YoY) and FY oncology tests ≈ 800,800 (+52% YoY), with clinical MRD tests at ≈ 769,700 for the year. Cash inflows were ≈ $30M in Q4 and > $100M for FY 2025. Additional business updates will be presented at the J.P. Morgan Healthcare Conference on January 13, 2026, and full audited results will be released in February 2026.
Octave Bioscience announced the appointment of Kirk Stockwood as Senior Vice President, Commercial on January 8, 2026.
Stockwood will lead commercial strategy as Octave scales its precision neurology platform. He brings over 20 years of specialty diagnostics experience and was most recently Vice President of Sales at Quanterix, where he led a global neurology and immunology team that delivered 12 consecutive quarters of double-digit revenue growth. His prior roles include commercial expansion work at Natera (NASDAQ: NTRA), 10x Genomics, Veritas Genetics, and Color Genomics. Leadership statements highlight his mandate to accelerate Octave’s commercial reach and advance its biomarker-driven solutions for multiple sclerosis and Parkinson’s disease.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
